No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 13 of the 40 quarters in the window, leaving 27 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 0.8x · 10Y median 1.7x · 24th percentile · as of Oct 6, 2026
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2023-09-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2023-09-29.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2023-09-29. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T19:02:07.629Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for InterCure Ltd. (INCR) stock was $5.33 as of Oct 6, 2026, 2:44 PM EDT, down 2.13% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -32.6% · 3-year avg -10.1%/yr · 5-year avg -30.9%/yr
InterCure Ltd., including its subsidiaries, is actively involved in the entire lifecycle of medical cannabis products. This encompasses everything from initial research and cultivation to manufacturing, marketing, and global distribution, serving both the Israeli market and international territories.
Drug Manufacturers - Specialty & Generic · Herzliya, TA
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
N/A
vs Estimate
N/A
Revenue
$70.09M
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1INCR | $63.19M | $5.33 | -2.13% | -32.59% | -30.85% | N/A | N/A |
| 2PLRX | $63.16M | $1.02 | -0.97% | -32.11% | -43.17% | N/A | vs INCR |
| 3RNXT | $63.52M | $1.41 | -4.08% | +11.31% | -23.80% | N/A | vs INCR |
| 4ALPS | $63.56M | $0.38 | -4.50% | N/A | N/A | N/A | vs INCR |
| 5HRTX | $62.56M | $0.33 | -10.68% | -71.80% | -48.61% | -31.88% | vs INCR |
| 6GOSS | $64.83M | $10.61 | -0.38% | -94.75% | -59.51% | N/A | vs INCR |
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$5.33
High
N/A
